| 23.5306 -0.059 (-0.25%) | 12-08 15:34 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.71 | 1-year : | 35.87 |
| Resists | First : | 26.29 | Second : | 30.71 |
| Pivot price | 23.54  |
|||
| Supports | First : | 20.36 | Second : | 16.7 |
| MAs | MA(5) : | 23.43  |
MA(20) : | 22.86 |
| MA(100) : | 16.51 |
MA(250) : | 0 | |
| MACD | MACD : | 1.5 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 52.8 |
D(3) : | 55.7 |
| RSI | RSI(14): 60.8 |
|||
| 52-week | High : | 30.47 | Low : | 10.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EWTX ] has closed below upper band by 49.7%. Bollinger Bands are 44.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 26 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 24.29 - 24.43 | 24.43 - 24.55 |
| Low: | 23.16 - 23.31 | 23.31 - 23.44 |
| Close: | 23.37 - 23.61 | 23.61 - 23.83 |
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Sun, 07 Dec 2025
Schroder Investment Management Group Has $1.98 Million Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Fri, 05 Dec 2025
Analysts Offer Insights on Healthcare Companies: Nano-X Imaging (NNOX), Edgewise Therapeutics (EWTX) and BioNTech SE (BNTX) - The Globe and Mail
Wed, 03 Dec 2025
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Eastern Progress
Wed, 03 Dec 2025
XTX Topco Ltd Takes Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Tue, 02 Dec 2025
Edgewise Therapeutics (Nasdaq: EWTX) issues inducement option for 26,250 shares at $26.04 - Stock Titan
Fri, 21 Nov 2025
Will Edgewise Therapeutics (EWTX) Gain a Commercial Edge With Its New Board Appointment? - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 106 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 106.7 (%) |
| Shares Short | 10,050 (K) |
| Shares Short P.Month | 8,620 (K) |
| EPS | -1.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.7 % |
| Return on Equity (ttm) | -30.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -132 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | -15.01 |
| PEG Ratio | 0 |
| Price to Book value | 4.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|